VERTEX PHARMACEUTICALS INC / MA (VRTX)
$541.15-$6.40 (-1.17%) Today
Duncan McKechnie - OfficerVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 14,094 | $6.63M |
| Grant or award | 4 | 16,634 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
119 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ourania Tatsis - Officer | Grant or award | Common Stock | 8,251 | $0.00 | - | |
 Amit Sachdev - Officer | Grant or award | Common Stock | 8,251 | $0.00 | - | |
| Bruce I. Sachs - Director | Grant or award | Deferred Stock Units | 99.94 | $475.28 | $47K | |
 Alan M. Garber - Director | Grant or award | Deferred Stock Units | 31.56 | $475.28 | $15K | |
| Ourania Tatsis - Officer | Open-market sale | Common Stock | 1,500 | $524.99 | $787K | |
| Duncan McKechnie - Officer | Open-market sale | Common Stock | 1,541 | $519.00 | $800K | |
| Joy Liu - Officer | Open-market sale | Common Stock | 828 | $502.71 | $416K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 596 | $482.50 | $288K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,020 | $462.17 | $471K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 4,062 | $450.00 | $1.83M | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,745 | $450.00 | $785K | |
| Joy Liu - Officer | Open-market sale | Common Stock | 828 | $439.91 | $364K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,974 | $450.00 | $888K | |
| Mark E. Bunnage - Officer | Open-market sale | Common Stock | 33 | $453.45 | $15K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,354 | $453.45 | $614K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 6,988 | $450.00 | $3.14M | |
 Suketu Upadhyay - Director | Derivative | Common Stock | 796 | - | - | |
| Suketu Upadhyay - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
| Suketu Upadhyay - Director | Grant or award | Deferred Stock Units | 796 | - | - | |
| Nancy Thornberry - Director | Grant or award | Common Stock | 472 | $0.00 | - | |
| Nancy Thornberry - Director | Derivative | Common Stock | 398 | - | - | |
| Nancy Thornberry - Director | Grant or award | Stock Option (Right to Buy) | 1,433 | $0.00 | - | |
| Nancy Thornberry - Director | Grant or award | Deferred Stock Units | 398 | - | - | |
| Jennifer Schneider - Director | Grant or award | Common Stock | 472 | $0.00 | - | |
| Jennifer Schneider - Director | Derivative | Common Stock | 796 | - | - | |
| Jennifer Schneider - Director | Grant or award | Stock Option (Right to Buy) | 1,433 | $0.00 | - | |
| Jennifer Schneider - Director | Grant or award | Deferred Stock Units | 796 | - | - | |
| Bruce I. Sachs - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
 Diana McKenzie - Director | Grant or award | Common Stock | 943 | $0.00 | - | |
| Diana McKenzie - Director | Derivative | Common Stock | 796 | - | - | |
| Diana McKenzie - Director | Grant or award | Deferred Stock Units | 796 | - | - | |
| Joy Liu - Officer | Open-market sale | Common Stock | 1,104 | $425.02 | $469K | |
 Michel Lagarde - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
| Alan M. Garber - Director | Grant or award | Common Stock | 472 | $0.00 | - | |
| Alan M. Garber - Director | Grant or award | Stock Option (Right to Buy) | 1,433 | $0.00 | - | |
| Lloyd Carney - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
| Sangeeta N. Bhatia - Director | Grant or award | Common Stock | 943 | $0.00 | - | |
| Sangeeta N. Bhatia - Director | Open-market sale | Common Stock | 318 | $423.73 | $135K | |
| Suketu Upadhyay - Director | Grant or award | Deferred Stock Units | 80.51 | $442.50 | $36K | |
| Bruce I. Sachs - Director | Grant or award | Deferred Stock Units | 107.35 | $442.50 | $48K | |
| Alan M. Garber - Director | Grant or award | Deferred Stock Units | 33.9 | $442.50 | $15K | |
| Joy Liu - Officer | Open-market sale | Common Stock | 978 | $449.17 | $439K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Bruce I. Sachs | Director | 1,210 | $663K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
VERTEX PHARMACEUTICALS INC / MA (VRTX) had 13 insider filings in the last 90 days, with the most recent on 2026-07-23. The full record for VRTX runs to 119 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of VRTX were filed in the last 90 days. 4 purchases are on record for this company.
9 insider sales of VRTX were filed in the last 90 days, totaling $6.63M.
This page tracks VRTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VRTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
